Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts. more
Time Frame | ALLR | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.61% | -3.39% | -3.47% |
1-Month Return | -19.83% | -3.25% | -0.29% |
3-Month Return | -57.82% | -11.61% | 4.5% |
6-Month Return | -92.67% | -5.89% | 6.91% |
1-Year Return | -99.7% | 2.65% | 23.79% |
3-Year Return | -100% | 0.56% | 28.43% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 120.00K | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | 86.00K | 106.00K | 120.00K | 37.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":71.67,"profit":true},{"date":"2021-12-31","value":88.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":30.83,"profit":true}] |
Gross Profit | 120.00K | (86.00K) | (106.00K) | (120.00K) | (37.00K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-71.67,"profit":false},{"date":"2021-12-31","value":-88.33,"profit":false},{"date":"2022-12-31","value":-100,"profit":false},{"date":"2023-12-31","value":-30.83,"profit":false}] |
Gross Margin | 100.00% | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 10.24M | 9.23M | 26.56M | 16.89M | 17.89M | [{"date":"2019-12-31","value":38.55,"profit":true},{"date":"2020-12-31","value":34.75,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":63.61,"profit":true},{"date":"2023-12-31","value":67.37,"profit":true}] |
Operating Income | (17.61M) | (9.23M) | (26.56M) | (34.46M) | (17.93M) | [{"date":"2019-12-31","value":-1761100000,"profit":false},{"date":"2020-12-31","value":-922700000,"profit":false},{"date":"2021-12-31","value":-2655600000,"profit":false},{"date":"2022-12-31","value":-3446300000,"profit":false},{"date":"2023-12-31","value":-1792900000,"profit":false}] |
Total Non-Operating Income/Expense | (4.67M) | 1.67M | (1.80M) | (880.00K) | 4.96M | [{"date":"2019-12-31","value":-94.23,"profit":false},{"date":"2020-12-31","value":33.75,"profit":true},{"date":"2021-12-31","value":-36.41,"profit":false},{"date":"2022-12-31","value":-17.75,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (18.98M) | (7.23M) | (26.52M) | (17.58M) | (12.62M) | [{"date":"2019-12-31","value":-1897700000,"profit":false},{"date":"2020-12-31","value":-723400000,"profit":false},{"date":"2021-12-31","value":-2651500000,"profit":false},{"date":"2022-12-31","value":-1757900000,"profit":false},{"date":"2023-12-31","value":-1261800000,"profit":false}] |
Income Taxes | (4.58M) | (2.16M) | 133.00K | (1.52M) | (717.00K) | [{"date":"2019-12-31","value":-3441.35,"profit":false},{"date":"2020-12-31","value":-1624.81,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-1143.61,"profit":false},{"date":"2023-12-31","value":-539.1,"profit":false}] |
Income After Taxes | (14.40M) | (5.07M) | (26.65M) | (16.06M) | (11.90M) | [{"date":"2019-12-31","value":-1440000000,"profit":false},{"date":"2020-12-31","value":-507300000,"profit":false},{"date":"2021-12-31","value":-2664800000,"profit":false},{"date":"2022-12-31","value":-1605800000,"profit":false},{"date":"2023-12-31","value":-1190100000,"profit":false}] |
Income From Continuous Operations | (14.40M) | (5.07M) | (26.65M) | (16.06M) | (13.02M) | [{"date":"2019-12-31","value":-1440000000,"profit":false},{"date":"2020-12-31","value":-507300000,"profit":false},{"date":"2021-12-31","value":-2664800000,"profit":false},{"date":"2022-12-31","value":-1605800000,"profit":false},{"date":"2023-12-31","value":-1301700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (14.40M) | (5.07M) | (26.65M) | (16.06M) | (11.90M) | [{"date":"2019-12-31","value":-1440000000,"profit":false},{"date":"2020-12-31","value":-507300000,"profit":false},{"date":"2021-12-31","value":-2664800000,"profit":false},{"date":"2022-12-31","value":-1605800000,"profit":false},{"date":"2023-12-31","value":-1190100000,"profit":false}] |
EPS (Diluted) | (0.28) | (0.04) | (1.00M) | (18.53) | (29.23) | [{"date":"2019-12-31","value":-27.61,"profit":false},{"date":"2020-12-31","value":-4.08,"profit":false},{"date":"2021-12-31","value":-100000101.68,"profit":false},{"date":"2022-12-31","value":-1853,"profit":false},{"date":"2023-12-31","value":-2923,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ALLR | |
---|---|
Cash Ratio | 2.49 |
Current Ratio | 2.75 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ALLR | |
---|---|
ROA (LTM) | -47.72% |
ROE (LTM) | -121.82% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ALLR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.36 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.64 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ALLR | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.38 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Allarity Therapeutics Inc (ALLR) share price today is $1.056
Yes, Indians can buy shares of Allarity Therapeutics Inc (ALLR) on Vested. To buy Allarity Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALLR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Allarity Therapeutics Inc (ALLR) via the Vested app. You can start investing in Allarity Therapeutics Inc (ALLR) with a minimum investment of $1.
You can invest in shares of Allarity Therapeutics Inc (ALLR) via Vested in three simple steps:
The 52-week high price of Allarity Therapeutics Inc (ALLR) is $373.8. The 52-week low price of Allarity Therapeutics Inc (ALLR) is $0.9.
The price-to-earnings (P/E) ratio of Allarity Therapeutics Inc (ALLR) is
The price-to-book (P/B) ratio of Allarity Therapeutics Inc (ALLR) is 0.38
The dividend yield of Allarity Therapeutics Inc (ALLR) is 0.00%
The market capitalization of Allarity Therapeutics Inc (ALLR) is $2.06M
The stock symbol (or ticker) of Allarity Therapeutics Inc is ALLR